# AstraZeneca Plc Lynparza nearly doubled time patients lived with

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-lynparza-nearly-doubled-time-patients-lived-with/412783995
- Published: 2019-06-03T07:42:01+01:00
- Author: Charlotte Edwards

**[AstraZeneca Plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US
and Canada) today announced detailed results from the Phase III POLO trial at the
2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US (
Abs #LBA4). Results are today also published in The New England Journal of Medicine(
NEJM).

The POLO trial tested Lynparza (olaparib) tablets as 1st-line maintenance monotherapy
for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the
pancreas (pancreatic cancer) whose disease had not progressed following standard-
of-care platinum-based 1st-line chemotherapy.

Results from the trial showed a statistically-significant and clinically-meaningful
improvement in progression-free survival (PFS) for Lynparza vs. placebo, improving
the time without disease progression by a median of 7.4 months for patients treated
with Lynparza vs. 3.8 months for those on placebo (HR 0.53 [95% CI, 0.35-0.82], 
p=0.004). More than twice as many patients showed no disease progression both at
one year (34% on Lynparza vs. 15% on placebo) and two years (22% vs. 10%, respectively).

> **José Baselga, Executive Vice President, Oncology R&D, said:** “These unprecedented
> results raise new hope for patients that have seen little progress over a long
> period of time. From as early as six months after initiation, more than twice 
> as many patients taking Lynparza lived without progression of their disease compared
> to those on placebo and we are now working with regulatory authorities to bring
> Lynparza to patients as quickly as possible.”

> **Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief
> Medical Officer, MSD Research Laboratories, said: **“We are encouraged by the 
> results of the POLO trial which showed a considerable reduction in risk of disease
> progression or death with Lynparza for germline BRCA-mutated metastatic pancreatic
> cancer patients who did not progress on chemotherapy. Currently less than 3% of
> metastatic pancreatic cancer patients survive more than five years after diagnosis.
> The results of this trial reinforce MSD and AstraZeneca’s commitment to develop
> innovative treatments for cancers with few options.”

> **Hedy L. Kindler, MD, co-principal investigator of the POLO trial and Professor
> of Medicine, University of Chicago Medicine, said:** “Despite efforts to identify
> therapies, targeted or combination treatments to improve patient outcomes, pancreatic
> cancer remains an area of high unmet need. The results of the POLO trial may open
> the door to a new era of personalised, biomarker-led care in metastatic pancreatic
> cancer and reinforces the importance of knowing BRCA status at diagnosis.”

Share on:
